IMG_E1413

コメント

  • コメント (10)

  • トラックバックは利用できません。

  1. Diflucan’s efficacy can be reduced by concomitant use of rifampin.

  2. Multiple drug interactions stem from its inhibition of human CYP2C9 and CYP3A4.

  3. Diflucan is often the reference agent in comparative antifungal clinical trials.

  4. Multiple drug interactions stem from its inhibition of human CYP2C9 and CYP3A4.

  5. Excreted in breast milk, so the risk-benefit must be weighed during lactation.

  6. Diflucan exposure is a major risk factor for the development of azole-resistant candidiasis.

  7. Development of the IV formulation expanded use to critically ill and unable-to-swallow patients.

  8. Excellent CSF penetration makes it a mainstay for cryptococcal meningitis suppression.

  9. Transient, asymptomatic liver enzyme spikes are common and often do not require discontinuation.

  10. A post-antimicrobial effect has been demonstrated against some Candida species.